pMMR/MSS resectable Colon Cancer
Conditions
Brief summary
Data generation through multi-omic exploration of blood and tissue derived products. Correlation of molecular-biological features identified with pathological response.
Detailed description
Safety analysis. Frequency and severity of treatment emergent AEs, SAEs, irAEs. AEs leading to death, discontinuation of trial intervention or resulting in the participant not being suitable for surgery., Proportion of participants with pathological response, determined by local assessment., Survival time defined from Superhero ICF signature to death from any cause. Proportion of survivors at 2 years., Event free survival time (EFS) defined from Superhero ICF signature to recurrence evaluated by local assessment or death.
Interventions
DRUGJEMPERLI 500 mg concentrate for solution for infusion
Sponsors
UZ Leuven
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Data generation through multi-omic exploration of blood and tissue derived products. Correlation of molecular-biological features identified with pathological response. | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety analysis. Frequency and severity of treatment emergent AEs, SAEs, irAEs. AEs leading to death, discontinuation of trial intervention or resulting in the participant not being suitable for surgery., Proportion of participants with pathological response, determined by local assessment., Survival time defined from Superhero ICF signature to death from any cause. Proportion of survivors at 2 years., Event free survival time (EFS) defined from Superhero ICF signature to recurrence evaluated by local assessment or death. | — |
Countries
Belgium
Outcome results
None listed